RIBOBIO

RiboBio Co. is a leading oligonucleotide-based biotech enterprise in China with the world-class R&D team and the cutting-edge technologies. The company develops and supplies innovative DNA/RNA, RNAi and miRNA products, as well as provides diverse oligonucleotide related R&D services. RiboBio established a comprehensive oligonucleotide manufacturing facility (supporting low to large scale, low to high throughput, and cGMP production), equipped with the state-of-the-art instrumentation and advanced techniques, and supported by experienced personnel. This allows our company to manufacture oligonucleotides and related products of high standard and excellent quality for biomedical research and pharmaceutical use.
RIBOBIO
Industry:
Biotechnology Health Care Life Science Manufacturing Pharmaceutical
Founded:
2004-01-01
Address:
Guangzhou, Guangdong, China
Country:
China
Website Url:
http://www.ribobio.com
Total Employee:
101+
Status:
Active
Contact:
400-686-0075
Total Funding:
0
Technology used in webpage:
SPF Domain Not Resolving Apache ASP.NET Ajax WordPress 5.7 Alibaba HiChina DNS Baidu Maps Alibaba Cloud MailBox
Similar Organizations
EpiVax
EpiVax is an immunology company developing comprehensive analytical capabilities in the field of computational immunology.
Current Employees Featured
Founder
Investors List
CXVC
CXVC investment in Venture Round - RiboBio
Newest Events participated

Official Site Inspections
http://www.ribobio.com Semrush global rank: 9.16 M Semrush visits lastest month: 201
- Host name: 47.96.108.187
- IP address: 47.96.108.187
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai

More informations about "RiboBio"
About Ribobio | Ribobio
More than 200 professionals have joined RiboBio with Dr. Craig Mello (2006 Nobel Laureate, a member of the American Academy of Sciences) serving as the chairman of RiboBio Scientific Development Committee and Dr. Bill Zhang …See details»
RiboBio - Crunchbase Company Profile & Funding
RiboBio Co. is a leading oligonucleotide-based biotech enterprise in China with the world-class R&D team and the cutting-edge technologies. The company …See details»
公司介绍 | 锐博生物 - RiboBio
“锐博生物 RiboBio ”是中国高品质核酸产品代名词之一,为国内外超过 5000 家机构提供产品或服务,客户 SCI 文章累计超过 40,000多篇 ,合作客户包括诺贝尔奖得主实验室、知名科研机构和全球制药公司,锐博生物是亚洲知名的寡核酸原 …See details»
About Ribobio | RiboPharm CDMO/CMO
Guangzhou RiboBio Co., Ltd. Address:13-14/F, Innovation Building C3, 182 Kexue Avenue, Science Park Guangzhou 510663, China Service hotline:400-686-0075.See details»
Guangzhou Ribobio Co., Ltd. - synapse.zhihuiya.com
了解Guangzhou Ribobio Co., Ltd. (广州市锐博生物科技有限公司)公司的药物管线,治疗领域,技术平台,以及它的14篇文献,疾病领域:感染,技术平台:预防性疫苗,mRNA疫苗,药 …See details»
RiboBio - Funding, Financials, Valuation & Investors - Crunchbase
Jul 6, 2017 RiboBio Co. is a leading oligonucleotide-based biotech enterprise in China with the world-class R&D team and the cutting-edge technologies. ... Experience the new Crunchbase, …See details»
走进锐博 | 锐博制药 - RiboBio
锐博生物始终将致力于培养国际一流的智慧型人才作为公司的首要发展战略。公司由诺贝尔奖获得者、美国科学院院士Craig C. Mello博士担任科学发展委员会主席,中央组织部“千人计划”国家特聘专家张必良博士担任董事长,已吸引了200 …See details»
RiboBio - Guangzhou, Guangdong, China | SciRank
About RiboBio: Guangzhou RiboBio Co., Ltd (RiboBio) is a leading biotechnology company in China that focuses on providing ribonucleic acid (RNA) based products and services with a …See details»
Guangzhou RiboBio Co Ltd - PharmaSource
Guangzhou RiboBio Co., Ltd is a leading biotechnology company in China that specializes in providing ribonucleic acid (RNA) based products and services. ... RiboBio offers a …See details»
About RiboBio
RiboBio has participated in and accomplished projects of National High Technology Research and Development Plan, the National 863 Program, the Key New Drug Development Program of the State’s 12th Five-Year Plan, as well …See details»
RiboBio - Products, Competitors, Financials, Employees, …
RiboBio. Frequently Asked Questions (FAQ) When was RiboBio founded? RiboBio was founded in 2004. Where is RiboBio's headquarters? RiboBio's headquarters is located at 13th Floor, …See details»
RiboBio - Contacts, Employees, Board Members, Advisors & Alumni
RiboBio Co. is a leading oligonucleotide-based biotech enterprise in China with the world-class R&D team and the cutting-edge technologies. ... Products. Resources. Pricing. Resources. …See details»
RiboBio Co., Ltd. - CMOCRO - Domain Name
RiboBio Co. is a leading oligonucleotide-based biotech enterprise in China with the world-class R&D team and the cutting-edge technologies. The company develops and supplies innovative …See details»
RiboBio | TIDES Europe: Oligonucleotide and Peptide Therapeutics
Guangzhou RiboBio Co., Ltd. ("RiboBio"), founded in 2004, is a leading nucleic acids-based biotech company in China. With the world-leading oligonucleotide and mRNA technologies, …See details»
About RiboPharm | RiboPharm CDMO/CMO
Guangzhou RiboBio Co., Ltd. Address:13-14/F, Innovation Building C3, 182 Kexue Avenue, Science Park Guangzhou 510663, China Service hotline:400-686-0075See details»
Ribobio – Gene Editing, RNAi, Cellular Assay and Oligonucleotide …
RiboBio is committed to providing scientists with world-class CRISPR-Cas9, RNAi, ncRNA, qPCR reagents and high-content screening, animal study, NGS, RNA Libraries, cGMP manufacturing …See details»
New Collaboration Targets the Development of Oligonucleotides
Dec 1, 2017 RiboBio will provide new state-of-the-art facilities and support infrastructure, as well as trained scientists and researchers. The goal, according to the companies, is to establish …See details»
RiboPharm CDMO/CMO
RiboBio provides world-leading oligonucleotide-based drug technology platform and CDMO/CMO solutions, serving customers with comprehensive, highly customized, high-level nucleic acid …See details»
Mark Abraham Named New CEO of Registered Insurance Brokers …
3 days ago The Registered Insurance Brokers of Ontario (RIBO) Council is pleased to announce the appointment of Mark Abraham to the role of Chief Executive Officer, effective June 1, 2025 …See details»
RIBOs-new-CEO - insuranceinstitute.ca
1 day ago “[Abraham] will lead our team and organization in the successful execution of that plan, enhancing the impact of our regulatory initiatives, strengthening connections with both …See details»